Starting from more than 200 medicines in the pipeline (status January 2024) mentioned in The High Impact Reports of the International Horizon Scan Initiative, a selection of impactful medicines was made. Criteria such as new chemical entity and potential game changer in clinical...
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
The Beneluxa iniative identified thirteen impactful medicines suitable for joint HTA submission
Beneluxa General Assembly and Steering Committee Meeting – December 2024
On 9 December 2024, Luxembourg hosted the annual General Assembly of the Beneluxa Initiative, bringing together member states to review progress, exchange ideas, and plan for the future. The day was filled with presentations on ongoing activities, interactive workshops on key...
Belgium and the Netherlands opt for individual negotiations after a joint assessment of gene therapy Hemgenix®
As in every joint reimbursement process, the involved countries Belgium and the Netherlands, assessed the eligibility of Hemgenix® for joint negotiations after the recently finalised joint Health Technology Assessment process. Hemgenix® is a one-shot therapy for the treatment of...